Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Sep 2019 Planned End Date changed from 31 Aug 2023 to 31 Dec 2023.
- 23 Sep 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Dec 2019.
- 24 Jul 2019 Results assessing the proportion of patients achieving an objective response with palbociclib and cetuximab in recurrent or metastatic head and neck squamous cell cancer published in the Lancet Oncology